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A B S T R A C T
Donor T cell chimerism is associated with relapse outcomes after allogeneic stem cell transplantation (alloSCT)
for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). However, measures of statistical
association do not adequately assess the performance of a prognostic biomarker, which is best characterized
by its sensitivity and specificity for the chosen outcome. We analyzed donor T cell chimerism results at day
100 (D100chim) after myeloablative alloSCT for AML or MDS in 103 patients and determined its sensitivity
and specificity for relapse-free survival at 6 months (RFS6) and 12 months (RFS12) post-alloSCT. The area under
the receiver operating characteristic curve for RFS6 was .68, demonstrating only modest utility as a predic-
tive biomarker, although this was greater than RFS12 at .62. Using a D100chim threshold of 65%, the specificity
for RFS6 was 96.6%; however, sensitivity was poor at 26.7%. This equated to a negative predictive value of 88.5%
and positive predictive value of 57.1%. Changing the threshold for D100chim to 75% or 85% modestly im-
proved the sensitivity of D100chim for RFS6; however, this was at the expense of specificity. D100chim is
specific but lacks sensitivity as a prognostic biomarker of early RFS after myeloablative alloSCT for AML or
MDS. Caution is required when using D100chim to guide treatment decisions including immunologic ma-
nipulation, which may expose patients to unwarranted graft-versus-host disease.
© 2017 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights
reserved.
INTRODUCTION
Disease relapse is the most common cause of treatment
failure and mortality after allogeneic stem cell transplanta-
tion (alloSCT) for acute myeloid leukemia (AML) and
myelodysplastic syndromes (MDS). Therapeutic options for
post-alloSCT relapse of AML or MDS include chemothera-
py; hypomethylating agents, either alone or in combination
with donor lymphocyte infusions; or a second alloSCT.
However, overall, the outcomes of these patients are poor;
overall survival at 1 year is approximately 20%, and fewer than
10% survive beyond 1 year if they are unable to proceed with
intensive salvage measures, including a second alloSCT [1-5].
Given the lack of effective salvage therapies for relapsed
AML and MDS after alloSCT, strategies are required to iden-
tify patients at high risk of relapse, which may allow the
initiation of pre-emptive therapy to prevent relapse. These
biomarkers should be reproducible, highly sensitive, and spe-
cific for disease relapse and validated in independent cohorts.
The 2010 International Workshop on the Biology, Preven-
tion and Treatment of Relapse after AlloSCT identified several
candidate biomarkers that warranted further investigation
as prognostic tools for post-transplant relapse, including donor
chimerism [6]. Several reports have described incomplete
donor T cell chimerism as a risk factor for relapse of AML and
MDS after myeloablative conditioning alloSCT [7,8]. However,
descriptions of statistical associations are usually inade-
quate to describe the ability of a biomarker to accurately
distinguish between patients who will relapse and those who
will not [9]. For a biomarker that has been identified from
regression analyses to be effective in predicting future
outcome, the associated odds ratio must be of a magnitude
rarely observed in such analyses [10]. Instead, the perfor-
mance of a biomarker is best described by its sensitivity and
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specificity. To date, the performance characteristics of donor
T cell chimerism as a predictor for relapse has not been well
described. In this report we validate the observation that
donor T cell chimerism is associated with relapse-free sur-
vival (RFS) after myeloablative alloSCT for AML or MDS in an
independent cohort and describe the performance of donor
T cell chimerism as a predictive biomarker of early relapse
outcomes post-alloSCT, in particular with regards to its sen-
sitivity and specificity.
METHODS
Adult patients (≥18 years) who underwent myeloablative conditioning
followed by peripheral blood or bone marrow alloSCT from a matched sibling
or unrelated donor for AML or MDS at the Royal Melbourne Hospital between
2000 and 2016 were included in this retrospective analysis. Patients who
relapsed or died before day 100 post-alloSCT were excluded. This study was
approved by the Royal Melbourne Hospital institutional human research ethics
committee.
The myeloablative conditioning regimens used over this period in-
cluded cyclophosphamide 120 mg/kg in combination with either intravenous
busulfan 12.8 mg/kg or total body irradiation 12 Gy. The choice of condi-
tioning regimen was not protocolized and was according to physician
discretion. Graft-versus-host disease (GVHD) prophylaxis consisted of
cyclosporine 3 mg/kg i.v commencing day –1, with transition to an equiv-
alent oral dose upon recommencement of oral intake, and short-course
methotrexate 15 mg/m2 day +1 followed by 10 mg/m2 days 3, 6, and 11.
AlloSCT recipients from sibling donors also received prednisolone .5 mg/
kg/d days 14 to 34 decreasing to .25 mg/kg/d days 35 to 48, whereas
transplants from unrelated donors received T cell depletion with
antithymocyte globulin 4 mg/kg pre-alloSCT in divided doses (Thymoglobulin;
Genzyme Corporation, Cambridge, MA). Cyclosporine taper commenced from
day +100 or earlier depending on physician discretion due to perceived risk
of relapse or toxicity.
Chimerism Analysis
Donor–recipient chimerism analysis was performed routinely on day 100
post-alloSCT on peripheral blood samples collected in EDTA. Recipient samples
were separated into CD3-positive (T cell) and CD3-negative (non–T cell) frac-
tions using immunomagnetic cell separation with density gradient
centrifugation (RosetteSep; StemCell Technologies, VIC, Australia). PCR was
performed using oligonucleotide primers specific for short tandem repeats
that were identified pretransplant to distinguish donor from recipient DNA
(Invitrogen, Thermo Fisher Scientific Inc., Waltham, MA). Products were ana-
lyzed using a 3730 DNA Sequencer (Applied Biosystems, Foster City, CA), and
chimerism results were expressed as the percentage of donor-specific DNA
present.
Endpoints and Statistical Analysis
The primary objective of the study was to evaluate the sensitivity and
specificity of day 100 donor T cell chimerism (D100chim) as a predictor of
RFS 6 months (RFS6) and 12 months (RFS12) post-alloSCT, treated as binary
outcomes. Relapse of AML or MDS was defined as >5% blasts or unequivo-
cal morphologic dysplasia not attributable to other causes on bone marrow
aspirate and trephine biopsy morphology. Logistic regression was used to
investigate the relationships between RFS6 and RFS12, and D100chim; age;
sex; Disease Risk Index (DRI); cytogenetics; graft type; donor relation; and
use T cell depletion. D100chim was investigated as both a continuous vari-
able and using predefined thresholds of 55%, 65%, 75%, 85%, and 95%. DRI
was separated into 2 categories of low/intermediate or high/very high, as
previously defined [11]. Cytogenetics risk categories were defined accord-
ing to the refined Medical Research Council classification [12]. Variables found
to be statistically significant in univariate analyses were included in a mul-
tivariate model. Significance level was set at α < .05. Statistical analysis was
performed using R analysis software (Comprehensive R Archive Network
Project, Vienna, Austria).
RESULTS
In total, 103 patients were included in the analysis
(Table 1). Of the patients with AML, 72 (80%) were in com-
plete remission at the time of alloSCT, whereas 11 patients
(12.2%) underwent transplantation in early morphologic
relapse. Twelve patients with MDS (92.3%) had not received
any disease-modifying therapy before alloSCT, and 1 patient
had received the hypomethylating agent azacitidine without
response. Of the 49 patients (54.4%) who received trans-
plants from unrelated donors, 5 patients were mismatched
at a single HLA class II loci (DR or DQ), whereas the remain-
der were 10/10 matches. Thirty-eight patients (42.2%) received
glucocorticosteroids for GVHD prophylaxis in addition to
cyclosporine and short-course methotrexate.
The median duration of follow-up was 48.0 months
(interquartile range, 29.1 to 76.0). Rates of overall survival at
6 and 12 months post-alloSCT were 97.1% (95% confidence
interval [CI], 91.2% to 98.5%) and 91.0% (95% CI, 83.4% to 95.2%),
respectively. RFS6 and RFS12 were 85.4% (95% CI, 77.0% to
91.0%) and 73.2% (95% CI, 63.4% to 80.8%), respectively. The
cumulative incidence of relapse, with nonrelapse mortality
as a competing risk at 6 and 12 months post-alloSCT, was
13.6% (95% CI, 7.8% to 21.0%) and 23.8% (95% CI, 16.0% to 32.5%)
respectively. The cumulative incidence of extensive chronic
GVHD at 6 and 12 months was 36.9% (95% CI, 27.6% to 46.2%)
and 45.7% (95% CI, 35.8% to 55.0%), respectively.
Associations between D100chim and RFS6 and RFS12
The median D100chim was 96% (interquartile range, 89%
to 100%), and complete D100chim (defined as ≥95%) was
achieved by 62.2% of patients. Patients who received T cell
depletion paradoxically had a higher median D100chim com-
pared with patients who did not (100% versus 91.5%), although
this was confounded by the observation that a greater number
of patients who did not receive T cell depletion had bone
marrow grafts (34.5% versus 6.8%). On univariate analysis,
covariates significantly associated with RFS6 included
D100chim as a continuous variable as well as D100chim as
a binary variable dichotomized by prespecified thresholds of
65%, 75%, and 85% (Table 2). DRI was also significantly asso-
ciated with RFS6 (odds ratio [OR], 3.94; 95% CI, 1.22 to 12.60;
P = .020). Cytogenetic classification, donor relation, stem cell
source, or administration of T cell–depleting antibodies were
not significantly associated with RFS6. In a multivariate model
including DRI and D100chim, DRI (OR, 3.616; 95% CI, 1.03 to
Table 1
Patient and Treatment Characteristics
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Cy indicates cyclophosphamide; TBI, total body irradiation; Bu, busulfan.
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12.58; P = .04) and D100chim (OR, 1.06; 95% CI, 1.02 to 1.11;
P = .006) remained significantly associated with RFS6.
Ninety-seven patients had a complete 12-month follow-
up and were included in the analysis of associations with
RFS12. At 12 months, D100chim as a continuous variable, as
well as D100chim at thresholds of 65%, 75%, and 85%, was
significantly associated with RFS12. However, only the con-
tinuous variable remained significantly associated with RFS12
(OR, .95; 95% CI, .92 to .99; P = .01) in a multivariable model
also including DRI. There was only moderate correlation
between D100chim (ie, CD3-positive T cell) and CD3-negative
chimerism (Spearman correlation coefficient R = .46). There
was also no significant association between CD3-negative chi-
merism and RFS6 or RFS12, suggesting that D100chim was
not merely a surrogate for myeloid chimerism.
Sensitivity and Specificity of D100chim as a Predictor of
RFS6 and RFS12
We analyzed the performance of D100chim as a predic-
tor of RFS6 and RFS12 by generating receiver-operating
characteristic curves and calculating the sensitivity and speci-
ficity of D100chim at different predetermined threshold
values. The area under the receiver-operating characteristic
curve (AUC) for D100chim as a predictor of RFS6 was .68
(Figure 1). Using a D100chim threshold of 65%, the specific-
ity for RFS6 was 96.6%; however, sensitivity was poor at 26.7%.
In our study cohort this equated to a negative predictive value
of 88.5% and positive predictive value (PPV) of 57.1%. Chang-
ing the threshold for D100chim to 75% or 85% modestly
improved the sensitivity of D100chim for RFS6; however, this
was at the expense of specificity (Table 3). In our cohort, PPV
decreased when the D100chim was increased from 65% to
75% or 85%. The AUC for D100chim as a predictor of RFS12
was .62, which was lower than that observed for RFS6. In
keeping with this, D100chim at thresholds of 65%, 75%, and
85% demonstrated poorer sensitivity for RFS12 compared with
RFS6.
Given that DRI and D100chim were independently asso-
ciated with RFS6 in our multivariable model, we investigated
the utility of combining both variables for the prediction of
RFS6. The AUC of the multivariable regression model was .77,
demonstrating an improved ability to predict RFS6 com-
pared with D100chim alone. Accordingly, we devised a scoring
algorithm where high/very high DRI scored 1 point and
D100chim less than 65% scored 1 point. The specificity of a
total score of 1 or greater for RFS6 was 79.5% and sensitivi-
ty 66.7%. Using an alternative D100chim threshold of 75%
improved sensitivity at the expense of specificity. There was
no further benefit in sensitivity or specificity of using a
D100chim threshold of 85%.
Kinetics of T Cell Chimerism up to Day 100
T cell engraftment after alloSCT is a dynamic process that
may be reflected in the change in T cell chimerism over time,
particularly in the first few months after donor cell infu-
sion. Of the 103 patients in the D100chim cohort, there were
80 patients in whom T cell chimerism was examined between
day 30 and day 60 post-alloSCT in addition to D100chim. The
Table 2
Univariate Logistic Regression Analysis for Associations with RFS6 and RFS12
RFS6 RFS12
OR (95% CI) P OR (95% CI) P
Age .99 (.95-1.04) .76 1.00 (.97-1.05) .85
DRI
Low/intermediate Ref* Ref
High/Very high 3.94 (1.22-12.60) .02 2.55 (.91-7.05) .07
Cytogenetics
Favorable Ref Ref
Intermediate 1.62 (.26-31.45) .66 3.20 (.54-61.34) .29
Adverse 1.50 (.16-32.74) .74 2.29 (.28-48.93) .49
Stem cell source
Peripheral blood Ref Ref
Bone marrow 1.94 (.55-6.23) .27 1.02 (.33-2.87) .97
Donor type
Sibling Ref Ref
Unrelated .50 (.15-1.53) .24 .79 (.31-1.96) .61
T cell depletion .84 (.26-2.53) .76 1.35 (.54-3.41) .52
D100chim
Continuous† 1.06 (1.02-1.11) <.01 1.05 (1.01-1.09) <.01
≤65% 10.30 (2.03-58.49) <.01 8.75 (1.74-64.41) .01
≤75% 6.83 (1.71-27.10) <.01 6.64 (1.80-27.66) <.01
≤85% 6.13 (1.83-20.65) <.01 4.50 (1.50-13.86) <.01
≤95% 2.76 (.90-9.48) .09 1.52 (.61-3.83) .37
* Reference value.
† D100chim as a continuous variable decreasing from 100%.
Figure 1. Receiver operating characteristic curve of D100chim as a predic-
tor of RFS6.
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characteristics of this subset of patients did not differ sig-
nificantly from the original cohort with respect to age, sex,
disease type, DRI, donor relation, or use of T cell depletion.
The median T cell chimerism between days 30 and 60 was
93.5% (interquartile range, 85% to 98.3%). In 4 patients (5%)
T cell chimerism increased by 10% or greater from days 30
to 60 to day 100 post-alloSCT, and in another 4 patients T cell
chimerism decreased by 10% or greater over the same time
period. There was an association between patients who had
a falling chimerism (by 10% or greater) and RFS6 (OR, 18.8;
95% CI, 2.2 to 400.1; P = .01). The sensitivity of a decrease in
T cell chimerism by 10% or greater for RFS6 was 21.4% and
specificity was 98.5%. The PPV of this dynamic measure of T
cell chimerism was 75%; however, this was hampered by a
high rate of false negative predictions (78.6%).
DISCUSSION
The ability to accurately predict early relapse after alloSCT
is an area of significant clinical need, given the poor prog-
nosis of established relapse and the potential for pre-emptive
immunologic manipulation to mitigate relapse risk. Donor
T cell chimerism is particularly attractive as a candidate
biomarker given its ability to be performed on peripheral
blood samples and relatively widespread availability to the
extent that it is routinely performed post-alloSCT. In addi-
tion, from a mechanistic point of view, donor T cell chimerism
reflects the degree of donor T cell engraftment and by ex-
tension may be used to infer the availability of donor T cells
to exert a graft-versus-leukemia effect. Several groups have
described an association between donor T cell chimerism and
relapse risk post-alloSCT; however, the interpretation of these
reports have been hampered by patient and disease heter-
ogeneity [13,14]. In the largest homogeneous cohort of AML/
MDS patients reported to date with respect to post-transplant
T cell chimerism, Lee et al. [8] reported an association between
day 100 T cell chimerism and relapse after myeloablative
alloSCT. In patients in first or second complete remission at
the time of alloSCT, donor T cell chimerism ≤ 85% was sig-
nificantly and independently associated with the cumulative
incidence of relapse at 3 years post-alloSCT, with a hazard
ratio of 2.4 (P = .02). In our study we likewise demonstrate
that D100chim is significantly associated with RFS6 and RFS12,
both as a continuous variable and using thresholds of between
65% and 85%.
However, the utility of D100chim as a predictive biomarker
of relapse post-alloSCT is inadequately characterized by mea-
sures of association such as ORs in logistic regression models.
For a biomarker to accurately predict prognosis, the distri-
butions of the biomarker in patients that have disease/
relapse or not must be sufficiently separated to allow
dichotomous classification [9]. This frequently, although in-
directly, corresponds to a strength of association rarely
observed in logistic regression models [10]. Therein lies the
considerable difference between statistical methodology for
investigation of classification rather than association. Thus,
rather than measures of association, the performance of a di-
agnostic or predictive tool is best described by the AUC of a
receiver-operating-characteristic curve or, when using a binary
classification tool, the sensitivity and specificity. We dem-
onstrate that the AUC of D100chim as a predictor of RFS6 was
.68, where only values of greater than .7 would be consid-
ered a reasonably predictive tool. When using D100chim as
a binary classification tool using a threshold of 65%, this dem-
onstrated high specificity (96.6%) for RFS6 but poor sensitivity
(26.7%). Increasing the D100chim threshold to 75% or 85% only
modestly improved sensitivity, at the expense of specificity.
In our patient cohort the high specificity but low sensitivity
of D100chim corresponded to a high NPV but poor PPV. In
practical terms, 43% of patients with D100chim of less
than 65% will be incorrectly classified as at risk of relapse
(false-positive predictions). This suggests that patients
with a low D100chim may not universally require potent
immunomodulatory therapy, such as donor lymphocyte in-
fusions, which are associated with a high rate of GVHD
toxicity.
In clinical practice, physicians often use a combination
of biomarkers that increase the power of prediction com-
pared with 1 marker alone. DRI has been validated in
several cohorts as independently associated with overall
survival and RFS after alloSCT [11,15]. When we combined
DRI and D100chim, sensitivity was improved; however, in
our cohort this did not translate to an improved PPV because
of the presence of an increased number of false-positive
predictions.
The strength of our analysis is the use of a homogenous
patient cohort of AML/MDS and myeloablative condition-
ing. In addition, our analysis of the sensitivity and specificity
of D100chim is unique. This was facilitated by the selection
of primary outcomes as dichotomous outcome variables. Fur-
thermore, our choice of RFS6 and RFS12 as the primary
endpoints of the analysis recognized that the prognostic
impact of D100chim is likely to be time-dependent; that is,
the predictive ability of D100chim for relapse is likely to de-
crease over time. This was confirmed by our observation that
sensitivity of D100chim for predicting RFS6 was greater than
RFS12. We hypothesized that extending the duration of
minimum follow-up (eg, RFS24 or RFS36) would reveal a
similar pattern. Our study had a relatively modest sample size,
which likely contributed to the lack of association observed
between cytogenetic risk group and RFS. However, we doubt
that our analysis of D100chim would be significantly altered
in a larger cohort because we were able to replicate the as-
sociation between D100chim and RFS as previously reported
in the literature. Our cohort also demonstrated some heter-
ogeneity with regards to disease risk and donor source;
however, it is unlikely that these factors would have signifi-
cantly impacted the results.
Table 3












≤65% 26.7 96.5 57.1 88.5
≤75% 33.3 93.2 45.5 89.1
≤85% 46.7 87.5 38.9 90.6
DRI + D100chim
≤65% 66.7 79.5 35.7 93.3
≤75% 73.3 78.4 36.7 94.5
≤85% 73.3 73.9 32.4 94.2
RFS12
D100chim
≤65% 20.0 97.5 71.4 77.8
≤75% 28.0 94.4 63.6 79.1
≤85% 36.0 88.9 52.9 80.0
DRI + D100chim
≤65% 52.0 80.6 48.1 82.9
≤75% 60.0 51.7 51.7 85.3
≤85% 60.0 76.4 46.9 84.6
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Biomarkers predictive of relapse post-alloSCT are desper-
ately required to identify patients who may benefit from post-
transplant immunologic strategies to prevent relapse. Other
than donor chimerism, minimal residual disease is another
candidate biomarker increasingly described as being asso-
ciated with relapse in patients with AML [16-18]. However,
as we and others have described, the performance of these
biomarkers as prognostic tools requires further character-
ization, particularly with regards to sensitivity and specificity.
For the moment we encourage caution when using D100chim
as a predictor of early relapse and mortality after
myeloablative alloSCT in AML and MDS, because it demon-
strates a high specificity but lacks sensitivity, which in our
cohort corresponded to a poor PPV and a high rate of false-
positive predictions. Clinicians should thus tread carefully
when using D100chim to guide post-transplant immuno-
logic therapy such as donor lymphocyte infusions, which are
associated with substantial rates of GVHD.
ACKNOWLEDGMENTS
Financial disclosure: The authors have nothing to disclose.
Conflict of interest statement: There are no conflicts of in-
terest to report.
REFERENCES
1. Levine JE, Braun T, Penza SL, et al. Prospective trial of chemotherapy and
donor leukocyte infusions for relapse of advanced myeloid malignancies
after allogeneic stem-cell transplantation. J Clin Oncol. 2002;20:405-412.
2. Eefting M, von dem Borne PA, de Wreede LC, et al. Intentional donor
lymphocyte-induced limited acute graft-versus-host disease is essential
for long-term survival of relapsed acute myeloid leukemia after
allogeneic stem cell transplantation. Haematologica. 2014;99:751-758.
3. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the
treatment of first hematological relapse after allogeneic stem-cell
transplantation in adults with acute myeloid leukemia: a retrospective
risk factors analysis and comparison with other strategies by the EBMT
Acute Leukemia Working Party. J Clin Oncol. 2007;25:4938-4945.
4. Schroeder T, Rachlis E, Bug G, et al. Treatment of acute myeloid leukemia
or myelodysplastic syndrome relapse after allogeneic stem cell
transplantation with azacitidine and donor lymphocyte infusions—a
retrospective multicenter analysis from the German Cooperative
Transplant Study Group. Biol Blood Marrow Transplant. 2015;21:653-660.
5. Craddock C, Labopin M, Robin M, et al. Clinical activity of azacitidine
in patients who relapse after allogeneic stem cell transplantation for
acute myeloid leukemia. Haematologica. 2016;101:879-883.
6. Kroger N, Bacher U, Bader P, et al. NCI First International Workshop on
the Biology, Prevention, and Treatment of Relapse after Allogeneic
Hematopoietic Stem Cell Transplantation: report from the Committee
on Disease-Specific Methods and Strategies for Monitoring Relapse
following Allogeneic Stem Cell Transplantation. Part I. Methods, acute
leukemias, and myelodysplastic syndromes. Biol Blood Marrow Transplant.
2010;16:1187-1211.
7. Huisman C, de Weger RA, de Vries L, Tilanus MG, Verdonck LF.
Chimerism analysis within 6 months of allogeneic stem cell
transplantation predicts relapse in acute myeloid leukemia. Bone Marrow
Transplant. 2007;39:285-291.
8. Lee HC, Saliba RM, Rondon G, et al. Mixed T lymphocyte chimerism after
allogeneic hematopoietic transplantation is predictive for relapse of acute
myeloid leukemia and myelodysplastic syndromes. Biol Blood Marrow
Transplant. 2015;21:1948-1954.
9. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med.
2006;355:2615-2617.
10. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of
the odds ratio in gauging the performance of a diagnostic, prognostic,
or screening marker. Am J Epidemiol. 2004;159:882-890.
11. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the
Disease Risk Index for allogeneic stem cell transplantation. Blood.
2014;123:3664-3671.
12. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic
classification in acute myeloid leukemia: determination of prognostic
significance of rare recurring chromosomal abnormalities among 5876
younger adult patients treated in the United Kingdom Medical Research
Council trials. Blood. 2010;116:354-365.
13. Koreth J, Kim HT, Nikiforow S, et al. Donor chimerism early after
reduced-intensity conditioning hematopoietic stem cell transplantation
predicts relapse and survival. Biol Blood Marrow Transplant.
2014;20:1516-1521.
14. Reshef R, Hexner EO, Loren AW, et al. Early donor chimerism levels
predict relapse and survival after allogeneic stem cell transplantation
with reduced-intensity conditioning. Biol Blood Marrow Transplant.
2014;20:1758-1766.
15. Lim AB, Roberts AW, Mason K, Bajel A, Szer J, Ritchie DS. Validating the
allogeneic stem cell transplantation disease risk index: sample size,
follow-up, and local data are important. Transplantation. 2015;99:128-
132.
16. Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual
disease as outcome predictor for AML patients in first complete
remission undergoing myeloablative or nonmyeloablative allogeneic
hematopoietic cell transplantation. Leukemia. 2015;29:137-144.
17. Zhou Y, Othus M, Araki D, et al. Pre- and post-transplant quantification
of measurable (“minimal”) residual disease via multiparameter flow
cytometry in adult acute myeloid leukemia. Leukemia. 2016;30:1456-
1464.
18. Kwon M, Martinez-Laperche C, Infante M, et al. Evaluation of minimal
residual disease by real-time quantitative PCR of Wilms’ tumor 1
expression in patients with acute myelogenous leukemia after allogeneic
stem cell transplantation: correlation with flow cytometry and
chimerism. Biol Blood Marrow Transplant. 2012;18:1235-1242.
844 E. Wong et al. / Biol Blood Marrow Transplant 23 (2017) 840–844
